Search results
Review the results we have found for you.
Use the filters to narrow down the results list and easily find the trial you look for.
1 Study StatusRecruiting1 A clinical trial to look at the safety and effectiveness of mosunetuzumab plus lenalidomide for treating follicular lymphoma
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Follicular Lymphoma
- NCT04246086, CO41942, 2023-507236-20-00
2 Study StatusCompleted2 A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Follicular Lymphoma,
- Diffuse Large B-Cell Lymphoma (DLBCL),
- Lymphoma
- NCT02729896, BO29561, 2015-004845-25
3 Study StatusCompleted3 Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Follicular Lymphoma,
- Leukemia,
- Chronic Lymphocytic Leukemia
- NCT03374137, ML30074
4 Study StatusCompleted4 Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Follicular Lymphoma
- NCT04034056, ML41215
5 Study StatusCompleted5 A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Follicular Lymphoma,
- Relapsed or Refractory Follicular Lymphoma,
- Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT02600897, GO29834, 2015-001999-22
6 Study StatusCompleted6 A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Follicular Lymphoma,
- Lymphoma
- NCT02631577, BO29562, 2015-002467-42
7 Study StatusCompleted7 A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Follicular Lymphoma,
- Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT02611323, GO29833, 2015-001998-40
8 Study StatusCompleted8 A Clinical Trial to Investigate the Effect of a Short Duration Infusion of Obinutuzumab in Patients with Previously Untreated Advanced Follicular Lymphoma (MO40597 study)
An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma (MO40597 study)
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Follicular Lymphoma
- NCT03817853, MO40597
9 Study StatusCompleted9 A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Chemotherapy in Participants With Non-Hodgkin Lymphomas
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Follicular Lymphoma,
- B-cell Non-Hodgkin Lymphoma
- NCT03467373, NP40126, 2017-003648-18
10 Study StatusTerminated10 A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Follicular Lymphoma,
- Diffuse Large B-Cell Lymphoma (DLBCL),
- Lymphoma
- NCT03135262, BH39147, 2016-002480-34